YOLFTbeta
30

ViGenCell Inc.

308080 · KQ · Healthcare / Biotechnology

4,520.00KRW-180.00 (-3.83%)

Price History

Full chart

Market Stats

Previous Close4,700.00
Open4,700.00
Day Range4,490.00 – 4,790.00
52-Week Range3,070.00 – 17,360.00
Volume68.06K
Market Cap119.92B
P/E (TTM)0.00
Forward P/E0.00
Dividend Yield0.00%
Beta1.86
50-Day Avg5,763.90
200-Day Avg7,510.15

About

ViGenCell Inc. provides immune cell therapy in South Korea. It develops ViTier, an antigen-specific killer T cell therapy, such as VT-EBV-N for NK/T Lymphoma indications and VT-Tri(1)-A for AML indications; ViMedier, a cord blood-derived myeloid suppressor cell therapy, including VM-GD for GvHD indications and VM-AD for atopic dermatitis indications; and ViRanger, an off-the-shelf allogenic universal T cell gene therapy comprising VR-CAR and VR-GDT for hepatoma and leukemia indications. The company was founded in 2013 and is based in Seoul, South Korea.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Kim Tai Gyu M.D., Ph.D.
  • Employees64
  • HeadquartersThe Reason Valley Knowledge Industry Complex, Seoul, South Korea, 08513, Korea
  • Websitehttps://www.vigencell.com

Leadership

  • Mr. Kim Tai Gyu M.D., Ph.D.Chief Executive Officer
  • Ms. Sohn Hyun Jung Ph.D.Head of ViTier Platform Group, Translational & Clinical Group
  • Mr. Cho Hyun II, Ph.D.Head of ViRanger Platform Group
  • Mr. Kyung-Mook KimVP and Head of Business Support Group & Management Administration · b. 1969
  • Hee-Baeg Choi Ph.D.Head of Precision Medicine Diagnostics Group & GMP Center
  • Su-Eon Kim Ph.D.Head of ViMedier Platform Group

Financials

Income Statement

Currency: KRW2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue15.03M00-0278.95M22.67M
Growth (%)--100.00%-----91.87%
Cost of Revenue000-0267.06M11.61M
Gross Profit15.03M00-011.88M11.06M
Gross Margin100.00%----4.26%48.79%
Operating Expense15.06B7.91B13.14B-20.08B15.34B17.12B
Operating Income-15.05B-7.91B-13.14B-18.21B-20.08B-15.33B-17.11B
Operating Margin-100094.40%-----5495.85%-75453.12%
EBITDA----14.19B-13.38B-10.06B-13.03B
EBITDA Margin------3606.84%-57459.08%
Net Income-22.43B-10.45B-11.11B-17.39B-17.88B-14.06B-16.32B
Net Income Margin-149218.83%-----5038.79%-71986.44%
R&D-4.42B6.82B12.29B15.45B11.58B14.75B
R&D as % of Total Revenue-----4150.08%65072.11%
Interest Expense0613.33M352.68M289.20M399.27M363.57M317.95M
Interest Expense % of Total Revenue0.00%----130.34%1402.25%

Balance Sheet

Currency: KRW2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets26.49B23.05B116.98B99.37B81.05B67.35B54.28B
Total Liabilities51.80B57.12B12.09B9.73B9.56B9.32B10.55B
Total Equity-25.32B-34.07B104.89B89.64B71.49B58.03B43.72B
Cash16.47B5.25B32.12B8.34B17.69B11.07B3.93B
Total Debt-328.02M-----
Net Debt------3.47B

Cash Flow

Currency: KRW2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-2.96B-8.19B-7.95B-11.09B-15.27B-10.90B-13.82B
Investing Cash Flow-6.19B-2.65B-68.73B-10.87B24.33B4.11B-
Financing Cash Flow20.00B-379.40M103.56B-1.82B296.66M169.48M-
Capital Expenditure987.52M1.77B11.52B13.65B1.02B112.54M821.75M
Free Cash Flow--9.97B-23.45B-24.77B-16.29B-11.01B-14.64B
FCF to OCF-121.67%294.77%223.40%106.71%101.03%105.95%

Earnings

Report DateSep 30, 2021Dec 31, 2021Mar 31, 2022Jun 30, 2022Sep 30, 2022Dec 31, 2022Mar 31, 2023Jun 30, 2023Sep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
EPS Estimate--------------------
EPS Actual-190.66-196.53-222.45-219.73-237.19-237.27-246.16-265.42-167.03-259.93-213.22-160.67-167.38-190.59-131.90-264.46-109.57-297.82-126.21-114.27
Surprise--------------------
Timing--------------------

Key Statistics & Ratios

Market Cap119.92B
Enterprise Value95.11B
Trailing P/E0.00
Forward P/E0.00
Price / Sales429.91
Price / Book3.02
Revenue (TTM)278.95M
Gross Profit (TTM)4.30M
EBITDA-10.23B
Profit Margin0.00%
Operating Margin-4861.71%
Return on Equity-20.23%
Return on Assets-11.91%
Shares Outstanding20.50M
Shares Float16.16M
Beta1.86
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Stock Splits

  • Jun 8, 20222:1